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introduction: To date, oncology patients are more dependent on non-cellular host 
defense against pathogens due to intensive (chemo)therapy-related bone marrow sup-
pression. Since data on complement functionality in oncology patients are limited, we 
aimed to investigate the innate complement function in relation to the type of malignancy 
and therapy in a longitudinal cohort of patients.
Methods: A large single-center, prospective non-intervention study was conducted, in 
which blood samples were taken from patients before, during, and after treatment with 
chemotherapy and/or subsequent admittance for (febrile) neutropenia.
results/findings: Analysis of 48 patients showed a high percentage of defects in 
complement activity of the alternative pathway (19.1%), the classical pathway (4.3%), or 
both (42.6%). Post hoc analysis of six different treatment protocols with more than three 
patients each showed distinct effects of specific therapies. Whereas patients treated 
according to the Ewing, EpSSG-rhabdomyosarcoma, or SIOP CNS germ cell tumor 
protocol showed no defects, patients treated according to the ALL-11 (leukemia), the 
EURAMOS I (osteosarcoma), or the ACNS (medulloblastoma) protocols showed an 
almost universal reduction in complement function. Although we could not explain the 
reduced complement functionality under all conditions, a strong effect was observed 
following high-dose methotrexate or ifosfamide.
conclusion: Acquired complement defects were commonly observed in more than 
50% of oncology patients, some of which associated with certain chemotherapeutic 
drugs. Additional studies are needed to determine the clinical and therapeutic context 
of complement defects and their possible effect on treatment outcome or the increased 
risk of infection.
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inTrODUcTiOn
Infection is the most important cause of treatment-related deaths 
in oncology and the second most common reason for hospitaliza-
tion during therapy (1, 2). The risk of infection and inflamma-
tion is increased in oncology patients due to treatment-induced 
neutropenia (3), making them more dependent on their innate, 
non-cellular immunity. This dependence on innate host defense 
mechanisms might be more prominent in children because of the 
relative immaturity of the immune system (4). Both the intactness 
of the barriers of skin, pulmonary, and gastrointestinal surface 
membranes as well as a functional innate immunity provide the 
most relevant defense against bacterial and fungal pathogens in 
oncology patients. To a large extent, this depends on complement 
proteins recognizing conserved so-called pathogen-associated 
molecular patterns (PAMPs) on the microbes on these surfaces 
upon invasion when these barriers are breached, for instance, by 
chemotherapy or radiation effects.
Although complement components are synthesized early in 
gestation, neonates show an immature innate immune response at 
birth, which poses an increased risk for infection. Concentrations 
of complement components are lower early during infancy com-
pared to adults but rapidly normalize within weeks after birth (5, 
6). Complement activation leads to opsonization of pathogens for 
phagocytosis, induces an inflammatory response, and eventually 
lyses pathogens via the membrane attack complex. Activation 
is induced via three distinctive pathways, the classical pathway 
(CP), the lectin pathway (LP), and the alternative pathway (AP) 
(7). Binding of antibody to antigen can activate the C1 complex 
(composed of C1q, C1r, and C1s), which will lead to the activa-
tion of C4 and C2, resulting in the generation of a C3-convertase 
C4b2a to activate the terminal pathway (8). In the LP, the binding 
of mannan-binding lectin (MBL), or one of the different ficolins 
(FCN), to their specific ligands will activate the MBL-associated 
serine proteases (MASPs), hereby generating a C3-convertase via 
a similar mechanism to the CP (9). Activation of the AP can occur 
via the spontaneous activation of C3 to C3(H2O), which, if not 
inhibited, generates a C3-convertase [C3(H2O)Bb], or via activa-
tion on apoptotic cells (10), or via amplification of the initial 
response of the CP or LP (11). The formation of a C3-convertase 
activates the terminal pathway, resulting in the formation of the 
membrane attack complex and lysis of the target cell (7, 12).
Although a role for complement factors has been described 
for the host immunosurveillance against cancer (13–15), recent 
papers have instead confirmed a potentially harmful role of 
complement via the active C3a and C5a fragments that may con-
tribute to the initiation of malignant cells (16, 17). Limited data 
have been published regarding the effect of cancer therapeutics 
on complement components, and either way, both the effect of 
therapy on the protein levels of complement components (18) 
or the effect of therapy on the functionality of the complement 
pathways have not been well studied to date (19, 20).
Our previous report on a small cohort of oncology patients 
during MBL-substitution therapy suggested preexisting defects in 
complement activation (19). To confirm these previously observed 
reductions in complement activation in oncology patients and to 
correlate the effect of chemotherapy on the complement system in 
greater detail, a longitudinal observational study was conducted 
in patients being treated for diverse malignancies, including 
hematological malignancies and various solid tumors.
MaTerials anD MeThODs
study Design and Protocol
Between 1 September, 2012 and 1 September, 2014, all pediatric 
oncology patients who were admitted to the oncology depart-
ment of the Emma Children’s Hospital, Academic Medical Center 
(AMC), Amsterdam, the Netherlands, were eligible for inclusion 
in the complement study (C2012). After inclusion, patients were 
anonymized after written informed consent from parents and 
children (>12  years) was obtained. The study was conducted 
according to the declaration of Helsinki and Good Clinical 
Practice. The study protocol was approved by the local ethics 
committee (CCMO registered NL39747.018.12).
Patient selection
Eligibility criteria included pediatric oncology patients, irrespec-
tive of the treatment of the tumor (e.g., chemotherapy, surgery, 
radiotherapy, or combinations hereof), who were admitted to the 
hospital for oncological treatment or admitted to the oncological 
ward for any other reason, such as, but not limited to, suspected 
or proven infection (Figure 1). Blood was drawn at specific time 
points (T), when possible, on the day of diagnosis (T =  IC), 
before the start of therapy (T = B), during therapy (T = D), and 
after therapy (T = A), and thereafter, during episodes of febrile 
neutropenia (FN; neutropenia <500 cells/μL) or periods of sus-
pected infection, continuing during admission with blood serial 
sampling every other day (T = 1, T = 2, etc.), only at moments 
of routine blood sampling for any clinical indication. The next 
time point was when the patient was recovered from FN (T = Q, 
recovery of FN) or proven infection.
end-Points
The primary end-points of the study were (1) the presence and 
prevalence of transient reduced complement functionality, (2) 
determining the effect of therapy and malignancy to reduced 
functionality of complement activation, i.e., the association of 
reduced complement functionality with specific therapeutic 
regimes or specific malignancies, if possible, and (3) determining 
the association of neutropenia and reduced complement func-
tionality. Data on the occurrence and duration of fever, (proven) 
infection, and medication were obtained from the patient files. To 
determine a possible effect of therapy, only the largest groups of 
patients with similar treatment were selected for further post hoc 
analysis. Observational periods were defined as the period of days 
between admittance to the hospital, often related to oncological 
treatment or FN, and time of discharge. Because characteristics 
related to therapy and course of disease could change over time, 
different observation periods per patient could be defined. 
Diagnostic results (neutropenia, cell counts, organ failure) and 
different clinical parameters (mucositis, general well-being) were 
analyzed in relation to complement function. Total levels of com-
plement component C3 (gram per Liter) and the complement C3 
FigUre 1 | Design of the complement study. (When possible) blood was obtained during diagnosis (T = IC). Further blood sampling of included patients took 
place during oncological treatment [before start (T = B), during (T = D), or after treatment (T = A)] or during admittance for any other reason, such as, but not limited 
to (suspected) infection or episodes of febrile neutropenia (FN). Serial blood samples were drawn every other day (T = 1, T = 3, T = 5, etc.) during admittance. After 
admittance for therapy or episodes of FN, patients were sampled when qualifying (T = Q) for therapy.
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activation-dependent split product C3d [compared to fully acti-
vated normal serum aged (NSA) for 1 week at room temperature] 
were both obtained from the diagnostic department.
Power analysis
Transient reduction of functionality of the AP of complement 
was first observed during an MBL-substitution study in MBL-
deficient patients. The number of patients required to determine 
a transient reduction of complement functionality was calculated 
at 24 patients. Although the activation of the AP is independent 
of the activation of the LP or CP, this clinical observational study 
was corrected for the distribution of MBL-deficiency within the 
normal population.
Blood samples
Blood samples from the patients were obtained during routine 
sampling. All blood samples were processed within 1  h, and 
serum, plasma, and buffy coat were isolated, according to the 
previously described protocols (19, 21), and stored at −80°C until 
use.
assays
Functionality of the three complement activation pathways was 
performed at Sanquin Research and the Landsteiner laboratory, 
AMC, Amsterdam, using the well-described commercially avail-
able Wielisa® Complement system Screen COMPL 300 (Wieslab, 
Lund, Sweden) (22, 23). The ELISA was developed according to 
the manufacturer’s instructions. Briefly, specific pre-coated plates 
for the different complement activation pathways were incubated 
with a fixed dilution of serum, depending on the pathway of inter-
est, and compared to a positive control (%PC), which is given the 
value 100%.
Due to the strong influence of MBL levels on the functionality 
of the LP (24), both MBL serum levels and MBL genotype were 
determined to confirm the results of the Wielisa®. MBL genotyp-
ing was performed by Taqman assay, as previously described (25). 
By random selection of five samples per patient (if a series of more 
was available), MBL serum levels were measured as described 
before (19). Briefly, after incubation of serum to mannan-coated 
plates, mannan-bound MBL was detected using biotinylated 
mouse-anti MBL (αMBL-1) (26) and compared to a serum pool 
(with a known concentration of 1.3 μg/mL).
The AP functionality was also measured by AP50 (i.e., the 
amount of serum needed for 50% hemolysis of rabbit erythro-
cytes by AP activation) (27). By incubating lower dilutions of 
serum with rabbit erythrocytes in the presence of calcium chela-
tors to prevent CP and LP activation, the functionality of the 
AP can be selectively assessed. Activation of the AP will result 
in lysis of the rabbit erythrocytes, and the increase in absorb-
ance of released hemoglobin can be measured in the cell-free 
supernatant as compared to a 100% lysis control obtained by 
incubation of the erythrocytes with saponin [reference values: 
75–125% (28)].
statistical analysis
The association between MBL levels and functionality was 
calculated using a one-phase association with ordinary fit (no 
restriction). To determine a temporal effect of therapy on the 
functionality of the complement system, patient samples were 
paired within the different chemotherapy sessions. Significance 
was calculated with a paired, two-sided T-test. Data are expressed 
as mean ± SD in case of normal distributed data, unless other-
wise mentioned, and as median (range) for not normally distrib-
uted data. P-values less than 0.05 were considered statistically 
significant.
resUlTs
Baseline characteristics
Patient characteristics are described in Table 1. The total number 
of patients included in C2012 was 48. Patients were coded CA-001 
to CA-048. The median age of the patients [27 males (56.3%), 21 
females (43.7%)] was 8.0 years (range: 0.3–17.6). The median fol-
low-up was 488.5 days (range: 49–727), for a total number of 794 
TaBle 1 | Patient characteristics.
Patient    sexa age 
(years)
Tumor Therapy protocol Follow-up 
(days)
Te MBl 
genotype
sb gc rd
CA-001 M 3.2 Ewing sarcoma S VIIIc EuroEwing 197 4 LXPA/LXPAf
CA-002 M 1.9 AML H Ib DB AML 01 727 8 HYPA/HYPA
CA-003 M 3.3 Neuroblastoma S IVa HR chemo 713 19 HYPA/LXPA
CA-004 F 3.4 Pre B ALL H Ia ALL-11 684 77 HYPA/HYPAf
CA-005 M 17.6 BNHL H IIb LMB 2001 C 684 14 HYPA/LXPA
CA-006 F 11.7 GCT S X MAKEI 96 150 3 LYPA/LYQA
CA-007 F 6.2 Pre B ALL H Ia ALL-11 676 43 HYPA/LYQAf
CA-008 M 17.0 GCT S X SIOP CNS GCT 2009 669 5 LYQA/LYQCf
CA-009 F 2.5 Pleuropulmonal blastoma S XIIa  Chemotherapy 656 17 HYPD/LXPA
CA-010 M 9.9 GCT S X SIOP CNS GCT 2009 655 3 LXPA/LYQAf
CA-011 M 15.6 Ewing sarcoma S VIIIc Ewing 2008 643 29 LYPB/LYQAf
CA-012 F 15.8 Osteosarcoma S VIIIa  EURAMOS I 641 28 LYPB/LYQAf
CA-013 M 14.9 Burkitt lymphoma H IIc COP COPADM1 630 7 HYPA/LYPB
CA-014 M 12.0 Hodgkin H IIa Euronet PHL CL1 616 9 HYPA/LYPB
CA-015 F 14.7 Osteosarcoma S VIIIa  EURAMOS I 599 28 HYPA/LYPAf
CA-016 M 3.9 Alveolar RMS S IXa EpSSG-RMS 2005 598 24 HYPA/LYPAf
CA-017 M 1.5 Neuroblastoma S IVa  Chemotherapy 588 0 n/a
CA-018 M 10.8 Burkitt lymphoma H IIc LMB 2001 588 23 HYPA/HYPA
CA-019 F 1.6 Ependymoma S IIIa  Chemotherapy 587 42 LXPA/LXPA
CA-020 M 16.3 ALL H Ia ALL-11 574 32 HYPA/LXPAf
CA-021 M 14.4 Ewing sarcoma S VIIIc Ewing 2008 567 12 LXPA/LYQAf
CA-022 M 12.8 Osteosarcoma S VIIIa EURAMOS I 329 17 LYPB/LXPAf
CA-023 M 6.5 T-ALL H Ia ALL-11 549 27 HYPD/HYPAf
CA-024 F 0.3 Infant ALL H Ia Interfant 06 HR 49 8 LXPA/LYQC
CA-025 M 12.7 GCT S X SIOP CNS GCT 96 532 12 LYPB/LYQCf
CA-026 M 2.9 Melanotic neuroectodermal 
tumor
S VIIIc  Chemotherapy 522 9 LYPA/LYQA
CA-027 M 1.7 Opticus glioma S IIIc SIOP-LGG 2004 507 14 HYPA/LXPA
CA-028 F 14.9 Anaplastic large-cell  
lymphoma
H II ALCL-99 490 14 HYPA/HYPD
CA-029 M 14.5 Hodgkin lymphoma H IIa Euronet PHL-C1 TG3 487 10 HYPA/LYPB
CA-030 M 14.5 Osteosarcoma S VIIIa  EURAMOS I 423 33 LYPB/LYQAf
CA-031 F 4.3 Atypical teratoid rhabdoid 
tumor
S IIIc Euro rhabdoid CNS 2010 405 19 LXPA/LYQA
CA-032 M 2.9 RMS D S IXa EpSSG-RMS 2005 SR 289 6 HYPD/LYQAf
CA-033 F 7.7 Osteosarcoma S VIIIa  EURAMOS I 375 25 LYQA/LXPAf
CA-034 F 7.5 Ewing sarcoma S VIIIc Ewing 2008 371 13 LYQC/LYPAf
CA-035 F 2.4 PNET S IIIc  HEADSTART III 371 12 HYPD/HYPA
CA-036 F 14.7 Osteosarcoma S VIIIa  EURAMOS I 367 13 HYPA/LYQAf
CA-037 M 13.8 Osteosarcoma S VIIIa  EURAMOS I 333 33 HYPA/LXPAf
CA-038 F 12.5 Medulloblastoma S IIIc ACNS0331 344 8 HYPD/HYPAf
CA-039 M 6.9 Medulloblastoma S IIIc ACNS0332 313 9 HYPA/LYPBf
CA-040 F 8.2 Medulloblastoma S IIIc ACNS0332 307 14 LXPA/LYQAf
CA-041 M 13.2 CNS germinoma S Xa CNS GCT 2009 293 2 n/af
CA-042 F 16.4 B-NHL H IIb B-NHL Skion 258 12 LYPB/LYQA
CA-043 F 1.8 ALL H Ia ALL-11 213 22 LXPA/LYQAf
CA-044 F 13.2 Osteosarcoma S VIIIa  EURAMOS I 60 12 HYPA/LYPBf
CA-045 M 0.7 Embryonal RMS S IXa EPSSG subgroup c 188 5 HYPA/LXPAf
CA-046 F 1.8 Ewing sarcoma S VIIIc EWING 2008 160 4 LXPA/LXPAf
CA-047 M 2.9 Hepatoblastoma S VII SIOPEL 3 SR 107 6 LXPA/LXPA
CA-048 F 5.3 Wilms tumor S VIa SIOP 2001 97 8 HYPA/HYPA
aF(emale) or M(ale).
bS(olid) or H(ematological) malignancy.
cClassification of diagnostic group of malignancy according to Steliarova-Foucher et al. (29).
dR(esection).
eT(imepoints).
fSelected for further analysis.
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time points. Each patient received a unique identification number 
and was followed during different admittances to the hospital. 
One patient (CA-017) was included but was never admitted to 
the hospital and therefore excluded from further analysis. The 
larger diagnostic groups analyzed were acute lymphoblastic leu-
kemia (ALL) (n = 5; 10.4%), osteosarcoma (n = 7; 14.6%), Ewing 
sarcoma (n = 5; 10.4%), rhabdomyosarcoma (n = 3; 6.3%), germ 
cell tumors (n = 3; 6.3%), and medulloblastoma (n = 3; 6.3%). 
TaBle 2 | complement activation functionality of patients within six different therapy protocols.
Patient  
(n = 5)
age 
(years)
Tumor Therapy Follow-up  
(days)
Time points  
(n = 201)
cP aP
Median% Pc (range) Median% Pc (range)
CA-004 3.4 Pre B ALL ALL-11 684 76a 85.2 0–123.2 38.7 0–113.5
CA-007 6.2 Pre B ALL ALL-11 676 43 91 11.1–109.8 77 0–112
CA-020 16.3 ALL ALL-11 574 32 86.5 1–120 49.5 0–118
CA-023 6.5 T-ALL ALL-11 549 27 80.5 2–124 17 0–135
CA-043 1.8 ALL ALL-11 213 22 103.8 86.4–106.2 81.4 79.9–100
Median (range) 574 (213–684) 32 (22–77) 87.3 (0–124) 48.7 (0–135)
Patients  
(n = 7)
age 
(years)
Tumor Therapy Follow-up  
(days)
Time points  
(n = 189)
cP aP
Median% Pc (range) Median% Pc (range)
CA-012 15.8 Osteosarcoma EURAMOS I 641 28 100 84.7–117.3 100 68.6–113.5
CA-015 14.7 Osteosarcoma EURAMOS I 599 28 96 14.4–116.4 70.5 2.1–100
CA-022 12.8 Osteosarcoma EURAMOS I 329 17 97.2 67–110 94.2 2–116
CA-030 14.5 Osteosarcoma EURAMOS I 423 33 91 53–121.2 81 4.9–115.4
CA-033 7.7 Osteosarcoma EURAMOS I 375 25a 106 59.9–133.6 87.7 11.5–120.4
CA-036 14.7 Osteosarcoma EURAMOS I 367 13a 101.5 33.3–134.7 79.8 32–105
CA-037 13.8 Osteosarcoma EURAMOS I 333 33a 103.3 0–139.5 95.9 0–217.3
Median (range) 375 (60–641) 25 (12–33) 100.0 (0–139.5) 87.60 (0–217.3)
Patients  
(n = 5)
age 
(years)
Tumor Therapy Follow-up  
(days)
Time points  
(n = 62)
cP aP
Median% Pc (range) Median% Pc (range)
CA-001 3.2 Ewing sarcoma EuroEwing 197 4 100 100–100 98 83–100
CA-011 15.6 Ewing sarcoma Ewing 2008 643 29 91 23.9–100.1 84.4 4.1–108
CA-021 14.4 Ewing sarcoma Ewing 2008 567 12 95.25 67.1–106.8 100 72.78–131.3
CA-034 7.5 Ewing sarcoma Ewing 2008 371 13 100 62.8–117.7 98.3 40.5–120.8
CA-046 1.8 Ewing sarcoma Ewing 2008 107 4 99.5 92–128.6 101.3 92.3–105
Median (range) 371 (107–643) 13 (4–29) 97.05 23.90–128.6 96.90 4.1–131.3
Patients  
(n = 3)
age 
(years)
Tumor Therapy Follow-up  
(days)
Time points  
(n = 35)
cP aP
Median% Pc (range) Median% Pc (range)
CA-016 3.9 Alveolar RMS EpSSG-RMS 05 598 24 97.65 75.4–111.4 78.3 7.6–102
CA-032 2.9 RMS EpSSG-RMS 05 289 6 93.05 32–112.7 62 1–86.2
CA-045 0.7 Embryonal RMS EpSSG sgc 188 5 113.8 94.24–130.1 46.62 22.5–128.4
Median (range) 289 (188–598) 6 (5–24) 99.10 32–130.1 66.83 1–128.4
Patients  
(n = 3)
age 
(years)
Tumor Therapy Follow-up  
(days)
Time points  
(n = 20)
cP aP
Median% Pc (range) Median% Pc (range)
CA-008 17.0 GCT SIOP CNS GCT 
2009
669 5 100 95.2–103.4 100 62.3–100
CA-010 9.9 GCT SIOP CNS GCT 
2009
655 3 100 98.3–100 96.3 73–100
CA-025 12.7 GCT SIOP CNS GCT 
1996
532 12 97.4 74–110.4 95 6.0–100
Median (range) 655 (532–669) 5 (3–12) 99.6 74–110.4 97.1 6.0–100
Patients  
(n = 5)
age 
(years)
Tumor Therapy Follow-up  
(days)
Time points  
(n = 31)
cP aP
(%Pc) (range) (%Pc) (range)
CA-038 12.5 Medulloblastoma ACNS0331 344 8 100.2 80.5–124.9 40.25 6.8–56.50
CA-039 6.9 Medulloblastoma ACNS0332 313 9 95.40 75.5–123.1 29.00 4.0–100.0
CA-040 8.2 Medulloblastoma ACNS0332 307 14 112.5 78.44–137 61.29 12.10–164.7
Median (range) 307 (307–344) 9 (8–14) 106.1 75.5–137 44.50 4.0–164.7
aDue the experimental and logistical error, not all samples could be measured.
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Detailed description of functionality of the complement system 
of the specific diagnostic groups is described in Table  2. The 
remainder of the patients (n = 21; 43.8%) was not analyzed for 
specific associations with therapy or malignancy, due to the low 
number of similar therapies or lack of shared diagnoses within 
the study population.
FigUre 3 | classical (cP) and alternative (aP) pathway complement 
activity at all time points in all patients of the c2012 study. (a) In 
13.5% of the time points showed a reduced functionality of the CP, and in 
18.9% a reduced AP activity was observed. (B) Reduced functionality of the 
CP was divided into specific pathway inhibition (n = 31; 4.6%) or coincided 
with reduced AP activity (n = 60; 8.8%). Specific AP defects accounted for 
11.5% (n = 75). The dotted line depicts the lower limit of functionality in 
controls, as defined by Seelen et al. (22) for CP functionality (abnormal 
<75%) and AP functionality (<40%) in the WIELISA assay. Functionality is 
depicted as percentage of a positive control (%PC).
FigUre 2 | lectin pathway functionality correlation with MBl-
concentration. (a) In a longitudinal series of more than five consecutive time 
points per patient, MBL concentrations were measured in oncology patients 
(●) and correlated to the LP functionality (r2 = 0.907). Functionality is 
depicted as percentage of a positive control (%PC). (B) MBL genotype was 
correlated to MBL serum levels. MBL deficiency as defined as MBL levels 
below 500 ng/mL is depicted as a dotted line. Because of the observed 
effects of chemotherapy of the pediatric ALL-11 protocol (○) on the lectin 
pathway of complement, these ALL patients were excluded from the analysis 
(n = 5) (Keizer et al., submitted). MBL deficiency as defined by MBL levels 
below 500 ng/mL is depicted by a dotted line.
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The lectin Pathway of complement
One single complete MBL-deficiency was observed in a 
patient with MBL protein levels below the detection limit 
(CA-025). This deficiency was confirmed by genotyping. No 
other complete genetic complement deficiencies were found 
within the included patients, since all patients showed normal 
functionality of the different activating pathways of comple-
ment during the observational period at several independent 
time points.
Activation of the LP of complement was directly related 
to MBL serum levels (r2 =  0.9071) (Figure  2A) and genotype 
(Figure 2B). Since MBL is a highly variable plasma protein based 
on genotype and acute phase response reactivity (30) (Appendix 
B in Supplementary Material), we focused in our subsequent 
analyses solely on the functionality of the CP and AP cascade of 
complement activation.
The classical and alternative Pathway  
of complement
The cutoff for abnormal functionality of the CP was measured 
by Wielisa® COMPL 300 set at <75% and for the functionality 
of the AP at <40% of the positive control levels (%PC) (22). We 
observed a wide range of complement activities in our patients for 
the CP, from being completely inactive to normal [median 96% 
(range 0–137.0%)]. This was also true for the AP activity [median 
79% (range 0–164.7%)] (Figure 3A).
No reduced functionality at any point was observed in 34.0% 
patients, whereas a reduced functionality was observed in both 
pathways in 42.6%, or in a single pathway in 23.4% (i.e., 4.3% in 
the CP and 19.1% in the AP).
In total, 24.8% (n =  166/669) of the time points analyzed 
showed a reduced functionality of the complement system in 
either the CP or the AP, or both (Figure 3A): specific CP defects 
were observed in 18.7% (n =  31/166) of all defects, whereas 
a reduction of the AP was seen in 45.2% (n =  75/166) of the 
time points (Figure 3B; Appendix C in Supplementary Material). 
A  reduction of CP functionality coincided with a reduction 
of the functionality of the AP in 36.1% (n =  60/166) of time 
points with reduced functionality (Figure 3B). Since there was 
not a complete overlap, our findings indicated that selective CP 
or AP defects in oncology patients may occur. The number of 
patients in which these specific defects in CP (4.6% of all time 
points) and or AP (11.2% of all time points) do not coincide 
is suggestive for the presence of some as yet unknown factors, 
which have a selective deleterious impact on these complement 
pathways.
FigUre 4 | The functionality of the complement system of patients within the different treatment protocols. (a) In patients with ALL, 47.6% (n = 79/200) of 
the time points showed a reduced functionality of the complement system. There were 63.3% (n = 50/79) and 91.1% (n = 72/79), which were related to the CP or AP, 
respectively. (B) In patients with osteosarcoma and treated according to the EURAMOS I protocol, 23 time points (12.2%) had a reduction in complement functionality. 
Of these, 23 moments 60.9% (n = 14/23) and 78.3% (n = 18/23) where in CP and AP, respectively. (c) Ewing sarcoma patients had in 14.5% (n = 9/62) a reduced 
functionality, but they were mostly related to the CP (88.9%, n = 8/9) and to a lesser extent to the AP (22.2%, n = 2/9). (D) Patients with rhabdomyosarcoma treated 
according to EpSSG protocol showed in 11.4% of the analyzed samples complement defects (n = 4), which were all related to the AP (100%). (e) Patients with germ 
cell tumors had no reduced functionality apart from a single time point in AP activity (5%, n = 1). (F) Patients with medulloblastoma had only defects in 41.9% of the 
samples (n = 13/31) and all were in the AP. Mean ± SEM are shown. Functionality is depicted as percentage of a positive control (%PC).
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correlation of complement Functionality 
to specific Protocols
To determine potential drug-induced inhibition on the comple-
ment system, the patients were analyzed in specific treatment-
related groups, and functionality was analyzed in relation to the 
harmonized therapy protocols used to treat these patients. Due 
to the heterogeneity of the patient population, the top six therapy 
groups were selected for further analysis of some of these oncologi-
cal patient subgroups (Table 2). All patients with ALL, patients with 
osteosarcoma (n =  6/7), and all patients with medulloblastoma 
showed reduced CP and/or AP functionality at several time points 
following chemotherapy, whereas patients with Ewing sarcoma 
or germ cell tumors had no significant reduction in complement 
activation upon treatment for their solid tumor (Figure 4).
Of the patients with clear abnormalities in the complement 
activation routes, we analyzed the six largest treatment regimens. 
Analysis of the different time points (n = 200) of the included 
ALL patients [n = 5, all treated according to the ALL-11 protocol 
(31)] showed a clear negative effect of chemotherapy on the com-
plement pathway activity. We observed only few reductions in 
complement activity of the CP (n = 5/77; 6.5%), compared to the 
AP (n = 27/77; 35.1%), whereas the majority of samples showed 
simultaneous reductions in both CP and AP activity (n = 45/77; 
58.4%) (Figure 5A).
FigUre 5 | Temporal effect of all-11 protocol on complement functionality. (a) Functionality of the complement system of all patients treated according to 
the ALL-11 (n = 5). The dotted line depicts the lower limit of functionality for CP functionality (<75%) and AP functionality (<40%) as determined for the WIELISA 
assay. In total, 77 time points showed a reduction in complement functionality in these ALL patients: 5 time points specific for the CP activity, 27 specific for the AP, 
and 45 specific for both the CP and AP activities. Functionality is depicted as percentage of a positive control (%PC). (B) Representative figure of one patient with 
ALL showing the different treatment compounds with the respective effect on the functionality of the complement system in a longitudinal setting (Cyclo: 
cyclofosfamide, Cyta: cytarabine, Dauno/6-MP/Eto: Daunorubicin/6-mercaptopurine/etoposide, VCR: vincristine, Pred/Dexa: prednisone/dexamethasone, ASNase: 
asparaginase, MTX: methotrexate). Functionality is depicted as percentage of a positive control (%PC). (c) Total C3 was measured and correlated to the AP 
functionality. Normal range for total C3 levels (0.9–1.8 g/L) is depicted in gray. (D) Complement activation product C3d was measured and correlated to AP activity. 
C3d levels are compared to fully activated normal serum aged for 1 week (NSA), normal ranges of C3d levels (0.5–3.1) are depicted in gray.
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Because of the high prevalence of the more common presence 
of combined defects in both the CP and AP in 60% of the ALL-11 
samples, a shared factor was suspected. Temporal analysis of the 
complement functionality in the individual patients was unable 
to distinguish a direct correlation to a therapeutic compound 
(Figure  5B). Upon analysis of total C3 levels to determine 
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possible reductions in protein synthesis or increases in comple-
ment consumption, we found neither any correlation with the 
detected defects in complement functionality (Figure  5C) 
nor with the levels of C3d, which can be used as a marker for 
complement activation and consumption (Figure 5D). The ratio 
between C3d and C3 can be used as a measure of C3 activation 
(32). No correlation was observed between the ratio of C3d and 
total C3 and functionality of the CP or the functionality of the 
AP (data not shown).
In the subgroup of osteosarcoma patients (n  =  7) treated 
according to the EURAMOS I protocol (33), a total of 189 time 
points were available for measuring the CP and AP. No correla-
tion explaining the specific reduction in complement functional-
ity of the CP or the reduced functionality of the CP and AP was 
detected (Figure 6A). On the other hand, patients receiving high-
dose methotrexate (HD-MTX, 12  g/m2) (Table  3) showed less 
AP functionality directly following MTX infusion [most clearly 
by combining the different time points (n =  21)] (Figure  6B), 
before and after HD-MTX of all osteosarcoma patients, which 
showed a significant and immediate decrease (p  <  0.001) 
(Figure 6C). To confirm these effects in a different method, AP 
activity was also tested in a hemolytic assay (AP50), demonstrat-
ing a similar decrease in AP functionality after infusion of MTX 
(p < 0.01) (Figure 6D). One pair of plasma samples was excluded 
(open symbol) because the patient received rescue-therapy 
(Rescuvolin™) for toxic MTX levels above the upper cutoff used 
(i.e., 10 μg/L after 24 h; blood levels were closely monitored as 
part of the protocol). This latter patient showed rapid recovery of 
AP functionality following rescue-therapy, supporting the direct 
effect of HD-MTX on the functionality of the AP.
Patients with Ewing sarcoma (n = 5) received a therapeutic 
drug regimen of which several compounds were shared with 
the other treatment subgroups with exception of the alkylating 
antineoplastic agents busulfan, melphalan, or treosulfan (33, 39) 
(Table  3). We observed a reduction in the functionality of the 
CP (n = 7/62; 11.3%), whereas a reduction in the AP activity or 
a combination of the AP and CP activities was negligible and 
only present once (n = 1/62; 1.6%). The treatment protocol for 
Ewing sarcoma is the only chemotherapeutic treatment protocol, 
which appeared to be associated with a specific reduction in the 
CP. Despite all efforts, we were unable to find a direct correlation 
between these shared or unique drugs and the complement activ-
ity measured in the functional assays.
Although patients with rhabdomyosarcoma received similar 
forms of chemotherapy as the patients with Ewing sarcoma 
(35, 40), only some time points showed a clear reduction in 
the AP complement activity (Figure  7A). Further analysis 
indicated that these reductions in AP activity were associated 
with ifosfamide (Figure 7B). Ifosfamide is also given to patients 
with osteosarcoma, Ewing sarcoma, or germ cell tumors, but 
the drug-related effect on the AP activity as observed in rhab-
domyosarcoma was not seen in these latter two groups. On the 
other hand, post hoc analysis of time points of the osteosarcoma 
patients receiving ifosfamide confirmed this drug-related 
association (Appendix D in Supplementary Material). No 
correlation of a complement defect with the dosage or other 
clinical parameters was found. Patients with a germ cell tumor 
were treated according to the SIOP CNS GCT protocol, which 
combines radiotherapy and chemotherapy (41, 42), but no 
specific relation with complement functionality was identified. 
The small number of patients and/or the limited longitudinal 
time series that were available in some of the patient subgroups 
make it difficult to establish a common cause for these transient 
reductions in complement functionality.
Patients with medulloblastoma (n = 3) were treated accord-
ing to the ACNS-protocol (37, 38), and all patients showed 
reduced AP activity at certain time points, while they kept 
an intact functionality of the CP (Figure 4F). In our post hoc 
analysis, we were unable to determine a possible correlation 
to therapy, neither chemotherapy nor radiotherapy, or other 
clinical parameters.
DiscUssiOn
Significant reductions in the activating pathways of the 
complement system were observed in oncology patients. We 
reproduced our previous observation, showing the reductions 
of complement activity following chemotherapy were transient 
of nature (15). In this clinical prospective study, some of onco-
logical treatment regimens were found to specifically affect 
one or more of the three different activating pathways of the 
complement system.
In 66% of the patients included, a defect in the CP and/or AP 
route was observed. A reduced functionality in both pathways 
was observed in 42.6% of the patients (n = 20/47) and in 23.4% 
of the patients (i.e., 4.3% in the CP and 19.1% in the AP) in a 
single pathway. Because of the variability of MBL levels in the 
blood samples (and only one completely MBL-deficient patient), 
the current analysis focused on the CP and AP pathways of 
complement.
In these 28 affected patients within the 6 different therapeutic 
groups, a total of 25% of the time points analyzed showed a 
reduced function of 1 or more of the activation pathways of the 
complement system. A reduced CP and AP activity was observed 
in 14 and 20% of all time points measured. Although there was 
considerable overlap between CP and AP defects, we identified 
a number of specific defects, suggesting the presence of as yet 
unidentified highly selective factors that may impact on these 
functional complement pathways.
In subsequent post  hoc analysis, specific chemotherapeutic 
drugs could be implicated in the inhibitory effect on the comple-
ment activity in different patient subgroups, as suggested for leu-
kemia, osteosarcoma, or CNS tumors. The effect of chemotherapy 
complement components has been previously tested in patients 
with breast cancer receiving epirubicin–docetaxel combination 
therapy (18).
As observed in our study, reduced functionality of the 
complement system could occur by inhibition, reduced produc-
tion, or by increased turnover and depletion of complement 
proteins. There are few studies pointing to a selective activation 
of the classical, lectin, and AP of complement in the presence 
of different malignancies (43, 44). Cancer cells are known to 
develop strategies to inhibit and evade complement activa-
tion on the membrane by the overexpression of regulatory 
FigUre 6 | classical (cP) and alternative (aP) pathway complement functionality of patients with osteosarcoma receiving high-dose methotrexate 
(MTX) treatment. (a) Functionality of the complement system of all patients (n = 7) with osteosarcoma showed few specific CP defects (n = 7) with a similar 
number of specific AP defects or defects in both pathways. The dotted line depicts the lower limit of functionality for CP functionality (<75%) and AP functionality 
(<40%) as determined for the WIELISA assay. Functionality is depicted as percentage of a positive control (%PC). (B) Representative figure of one patient with 
osteosarcoma showing the different treatment compounds with the respective effect on the functionality of the complement system in a longitudinal setting (Dex: 
cyclofosfamide, Eto: etoposide, Dox: doxorubicin, Cis: cisplatin, MTX: methotrexate). Functionality is depicted as percentage of a positive control (%PC). (c) 
Combined time points (n = 21) from all patients within the EURAMOS I protocol receiving high-dose MTX therapy. The CP was not affected before or after MTX, 
whereas the AP showed a significant decrease in functionality (***p < 0.001). Box whiskers depict the min–max values; mean is indicated by a plus symbol. 
Functionality is depicted as percentage of a positive control (%PC). (D) The activity of the alternative pathway measured by the ability to induce hemolysis of sheep 
erythrocytes (AP50) was significantly decreased following high-dose MTX therapy (**p < 0.01). Dotted lines represent the upper and lower limit of normal reference 
values. One patient (depicted in open symbol) showed an increase after MTX therapy and subsequent rescue-therapy with Rescuvolin™.
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proteins  (45,  46). Systemic inhibition of the complement 
system has not been described to date. However, if any of 
the malignant processes per  se were directly responsible for 
the systemic complement defects observed, the reduced func-
tionality of the complement system would have been already 
more prominently present before the start of  chemotherapy. 
FigUre 7 | classical (cP) and alternative (aP) pathway complement functionality of patients with rhabdomyosarcoma (rMs). (a) Functionality of the 
complement system of all patients (n = 3) with rhabdomyosarcoma show no specific CP defects, whereas there are few specific AP defects (n = 3) and a single 
combined defect. (B) Combined time points from all patients with rhabdomyosarcoma receiving ifosfamide. Although no reduced functionality was observed at all 
time points, the AP was significantly reduced following therapy, whereas the CP remained unaffected. Unpaired samples are depicted in gray. Dotted lines represent 
the lower cutoff of normal complement functionality. **p < 0.01; paired t-test (n = 7). Functionality is depicted as percentage of a positive control (%PC).
TaBle 3 | Overview of the most commonly used chemotherapeutic compounds in the different treatment protocols.
Malignancy all Osteosarcoma ewing sarcoma rhabdomyosarcoma germ cell tumor Medullablastoma
Therapy protocol all-11  
(31)
eUraMOs i  
(33)
ewing 1999  
(33)
ewing 2008  
(34)
epssg–rMs  
(35)
siOP cns  
gcT (36)
acns 0331  
(37)
acns 0332  
(38)
Actinomycin D + + +
Adriamycin + +
Asparaginase +
Busulfan/melphalan + +
Carboplatin + +
Cisplatin + + + + +
Cyclophosphamide +
Cytosine arabinoside +
Daunorubicin +
Doxorubicin + + +
Etoposide + + + + +
Fludarabine +
Ifosfamide + + + + +
Lomustine +
6-Mercaptopurine +
Methotrexate + +
Treosulfan/melphalan +
Vincristine + + + + + +
Vinorelbine +
Zoledronate +
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Subsequent effective therapeutic  sessions would reduce the 
tumor burden and hereby reduce the inhibitory  capacity of 
the cancer. Similarly, an increased and prolonged consumption, 
because of tumor cell death as induced by the chemotherapy, 
would have resulted in a more prominent inhibitory effect 
on the complement system in earlier therapeutic sessions. 
Reduction of the tumor load would reduce the amount of 
consumption of complement components. If an increased 
consumption could result in a reduced capacity to activate the 
activation pathway, this would not directly explain a selective 
inhibitory activation of different pathways depending on the 
therapeutic regimens. The direct effect of cancer therapeutics 
on complement components could only be demonstrated for 
the therapeutic compounds MTX and ifosfamide.
The strong correlation with specific treatment regimens 
suggests either a direct effect of the drugs as part of the 
chemotherapeutic regimens on the functionality of (specific) 
complement proteins or an indirect effect, either via the 
increased cell death of (malignant) cells and depletion of 
complement components as a consequence, or via the reduced 
production of complement proteins. We were unable to show 
an increase in consumption of C3 by increased levels of the 
split product C3d or a decreased protein level of C3 due to 
increased complement turnover or breakdown. This was also 
shown by the lack of correlation of the ratio of C3d and C3 and 
the functionality of the CP or the functionality of the AP. This 
underlines that the observed transient complement defects are 
neither related to increased consumption due to cell death nor 
to an inhibitory effect of the treatment on complement protein 
synthesis. These findings suggest that, downstream of C3, other 
late complement components of the common so-called late 
terminal complement pathway are involved in the observed 
combined CP and AP defects.
This study was sufficiently powered to determine the pres-
ence of transient reductions in complement activity in oncol-
ogy patients. However, the study was not specifically designed 
to determine a direct effect of specific therapies or the many 
combination of chemotherapeutic compounds on the comple-
ment system. Nonetheless, we were able to show a correlation 
between MTX and ifosfamide and their direct negative effect on 
the complement system.
Due to chemotherapy-related neutropenia, the oncology 
patients are more dependent on their innate non-cellular immu-
nity for the defense against pathogens. Reduction of complement 
activity could increase the rate of infection. Oncologic treatment 
is associated with a higher incidence of infection (47, 48), and this 
has been previously correlated to levels of complement proteins 
of different activation pathways (49–51). Due to the relative small 
number of patients included in the study and the heterogeneous 
composition of the patient population, a possible clinical associa-
tion between infection and reduced complement functionality 
was not feasible. In this study, the number of patients studied 
and the low number of proven microbial infections were too 
small to draw any conclusion but having demonstrated the high 
prevalence of acquired complement defects, prospective studies 
designed to investigate the potential link between complement 
and infection-risk has become a feasible next step. However, 
although reduced functionality of the complement system 
could be a risk factor for infection, it has been suggested that 
low-grade inflammation by deposition of sub-lytic amounts 
could be beneficial, by inducing specific signaling pathways for 
tumor survival and growth (52), and inhibition of complement 
could therefore be of therapeutic value for overall survival of 
the patient.
In summary, oncology patients frequently show transient 
complement activation defects. Certain chemotherapeutic drugs 
appear to be directly related to the reduction of the activity of one 
or more complement pathways. Now that we have established 
highly significant complement defects in some of the oncology 
treatment regimens, additional studies should be designed to 
determine the positive or negative effects of the complement 
system (antitumor and/or increased risk of infection), which 
may be more relevant in children being more dependent on the 
innate immune system than in adults, which may have preexist-
ing specific antibodies being largely absent in young oncology 
patients.
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